Neurodegeneration with brain iron accumulation

Folia Neuropathologica

Volumn 43, Issue 4, 2005, Pages 286-296

  Gregory, Allison ^a   Hayflick, Susan J ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Hallervorden Spatz syndrome; NBIA; PANK2; Pantothenate kinase associated neurodegeneration; PKAN

Indexed keywords

BACLOFEN; BOTULINUM TOXIN; COENZYME A; CYSTEINE; IRON; LEVODOPA; PANTOTHENATE KINASE; PANTOTHENATE KINASE 2; PANTOTHENIC ACID; TRIHEXYPHENIDYL; UNCLASSIFIED DRUG;

AUTOSOMAL RECESSIVE DISORDER; BASAL GANGLION; BRAIN DEPTH STIMULATION; BRAIN HEMOSIDEROSIS; BRAIN RADIOGRAPHY; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISEASE COURSE; DRUG MEGADOSE; DYSTONIA; ENZYME DEFICIENCY; ENZYME METABOLISM; ENZYME SYNTHESIS; EXTRAPYRAMIDAL SYNDROME; GENE FUNCTION; GENE MUTATION; HALLERVORDEN SPATZ DISEASE; HEMOSIDEROSIS; HISTOPATHOLOGY; HUMAN; INBORN ERROR OF METABOLISM; NERVE DEGENERATION; NEUROIMAGING; NEUROPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PREDICTION; PROTEIN FUNCTION; RETINOPATHY; REVIEW; SPASTICITY; SPEECH DISORDER; TISSUE SPECIFICITY; VITAMIN SUPPLEMENTATION;

ANIMALS; BRAIN; COENZYME A; DISEASE MODELS, ANIMAL; DROSOPHILA; HALLERVORDEN-SPATZ SYNDROME; HUMANS; IRON; MICE; MUTATION; NERVE DEGENERATION; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR);

EID: 30944445397     PISSN: 16414640     EISSN: 1509572X     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Afshar K, Gonczy P, DiNardo S, Wasserman SA. Fumble encodes a pantothenate kinase homolog required for proper mitosis and meiosis in Drosophila melanogaster. Genetics 2001; 157: 1267-1276.
2. Arawaka S, Saito Y, Murayama S, Mori H. Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for alpha-synuclein. Neurology 1998; 51: 887-889.
3. Baumeister FA, Auer DP, Hortnagel K, Freisinger P, Meitinger T. The eye-of-the-tiger sign is not a reliable disease marker for Hallervorden-Spatz syndrome. Neuropediatrics 2005; 36: 221-222.
4. Benke T, Hohenstein C, Poewe W, Butterworth B. Repetitive speech phenomena in Parkinson's disease. J Neurol Neurosurg Psychiatry 2000; 69: 319-324.
5. Benke T, Butterworth B. Palilalia and repetitive speech: two case studies. Brain Lang 2001; 78: 62-81.
6. Castelnau P, Cif L, Valente EM, Vayssiere N, Hemm S, Gannau A, Digiorgio A, Coubes P. Pallidal stimulation improves pantothenate kinase-associated neurodegeneration. Ann Neurol 2005; 57: 738-741.
7. Ching KH, Westaway SK, Gitschier J, Higgins JJ, Hayflick SJ. HARP syndrome is allelic with pantothenate kinase-associated neurodegeneration. Neurology 2002; 58: 1673-1674.
8. Curtis AR, Fey C, Morris CM, Bindoff LA, Ince PG, Chinnery PF, Coulthard A, Jackson MJ, Jackson AP, McHale DP, Hay D, Barker WA, Markham AF, Bates D, Curtis A, Burn J. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet 2001; 28: 350-354.
9. Defendini R, Markesbery WR, Mastri AR, Duffy PE. Hallervorden-Spatz disease and infantile neuroaxonal dystrophy. Ultrastructural observations, anatomical pathology and nosology. J Neurol Sci 1973; 20: 7-23.
10. Dooling EC, Schoene WC, Richardson EP, Jr. Hallervorden-Spatz syndrome. Archives of Neurology 1974; 30: 70-83.
11. Drayer B. Magnetic resonance imaging and brain iron: implications in the diagnosis and pathochemistry of movement disorders and dementia. Barrow Neurol Inst Q 1987; 15-30.
12. Egan RA, Weleber RG, Hogarth P, Gregory A, Coryell J, Westaway SK, Gitschier J, Das S, Hayflick SJ. Neuro-ophthalmologic and electroretinographic findings in pantothenate kinase-associated neurodegeneration (formerly Hallervorden-Spatz syndrome). Am J Ophthalmol 2005; 140: 267-274.
13. Gallucci M, Cardona F, Arachi M, Splendiani A, Bozzao A, Passariello R. Follow-up MR studies in Hallervorden-Spatz disease. J Comput Assist Tomogr 1990; 14: 118-120.
14. Galvin JE, Giasson B, Hurtig HI, Lee VM, Trojanowski JQ. Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology. Am J Pathol 2000; 157: 361-368.
15. Gitlin JD. Aceruloplasminemia. Pediatr Res 1998; 44: 271-276.
16. Guimaraes J, Santos JV. Generalized freezing in Hallervorden-Spatz syndrome: case report. Eur J Neurol 1999; 6: 509-513.
17. Hajek M, Adamovicova M, Herynek V, Skoch A, Jiru F, Krepelova A, Dezortova M. MR relaxometry and 1H MR spectroscopy for the determination of iron and metabolite concentrations in PKAN patients. Eur Radiol 2005; 15: 1060-1068.
18. Hallervorden J, Spatz H. Eigenartige Erkrankung im extrapyramidalen System mit besonderer Beteiligung des Globus pallidus und der Substantia nigra. Z Ges Neurol Psychiatr 1922; 79: 254-302.
19. Hallervorden J. Uber eine familiare Erkrankung im extrapyramidalen System. Dtsch Z Nervenheilkd 1924; 204-210.
20. Halliday W. The nosology of Hallervorden-Spatz disease. J Neurol Sci 1995; 134: 84-91.
21. Hayflick SJ, Penzien JM, Michl W, Sharif UM, Rosman NP, Wheeler PG. Cranial MRI changes may precede symptoms in Hallervorden-Spatz syndrome. Pediatr Neurol 2001; 25: 166-169.
22. Hayflick SJ. Pantothenate kinase-associated neurodegeneration. In: S Pulst (ed.). Genetics of Movement Disorders. Academic Press, San Diego, 2002.
23. Hayflick SJ, Westaway SK, Levinson B, Zhou B, Johnson MA, Ching KH, Gitschier J. Genetic, clinical and radiographic delineation of Hallervorden-Spatz syndrome. N Engl J Med 2003; 348: 33-40.
24. iggins JJ, Patterson MC, Papadopoulos NM, Brady RO, Pentchev PG, Barton NW. Hypoprebetalipoproteinemia, acanthocytosis, retinitis pigmentosa, and pallidal degeneration (HARP syndrome). Neurology 1992; 42: 194-198.
25. Hill JM, Switzer RC, III. The regional distribution and cellular localization of iron in the rat brain. Neuroscience 1984; 11: 595-603.
26. Hill JM. Brain Iron: Neurochemical and Behavioural Aspects. In: MB Youdim (ed.). Taylor & Francis, London, New York and Philadelphia 1988.
27. Jackowski S. Cell cycle regulation of membrane phospholipid metabolism. J Biol Chem 1996; 271: 20219-20222.
28. Johnson MA, Kuo YM, Westaway SK, Parker SM, Ching KH, Gitschier J, Hayflick SJ. Mitochondrial localization of human PANK2 and hypotheses of secondary iron accumulation in pantothenate kinase-associated neurodegeneration. Ann N Y Acad Sci 2004; 1012: 282-298.
29. Karim VV. Human pantothenate kinase 1 (PANK1) gene: characterization of the cDNAs, structural organization and mapping of the locus to chromosome 10q23.2-23.31. Am J Hum Genet 2000; 67: A984.
30. Koeppen AH, Dickson AC. Iron in the Hallervorden-Spatz syndrome. Pediatr Neurol 2001; 25: 148-155.
31. Kornyey S. Die Stoffwechechselstorungen bei der Hallervorden-Spatzschen Krankheit. Zeitschrift Neurol 1964; 178-183.
32. Kuo YM, Duncan JL, Westaway SK, Yang H, Nune G, Xu EY, Hayflick SJ, Gitschier J. Deficiency of pantothenate kinase 2 (Pank2) in mice leads to retinal degeneration and azoospermia, Hum Mol Genet 2005; 14: 49-57.
33. Luckenbach MW, Green WR, Miller NR, Moser HW, Clark AW, Tennekoon G. Ocular clinicopathologic correlation of Hallervorden-Spatz syndrome with acanthocytosis and pigmentary retinopathy. American Journal of Ophthalmology 1983; 95: 369-382.
34. Miyajima H, Adachi J, Tatsuno Y, Takahashi Y, Fujimoto M, Kaneko E, Gitlin JD. Increased very long-chain fatty acids in erythrocyte membranes of patients with aceruloplasminemia. Neurology 1998; 50: 130-136.
35. Morphy MA, Feldman JA, Kilburn G. Hallervorden-Spatz disease in a psychiatric setting [see comments]. J Clin Psychiatry 1989; 50: 66-68.
36. Mutoh K, Okuno T, Ito M, Nakano S, Mikawa H, Fujisawa I, Asato R. MR imaging of a group I case of Hallervorden-Spatz disease. J Comput Assist Tomogr 1988; 12: 851-853.
37. Neumann M, Adler S, Schluter O, Kremmer E, Benecke R, Kretzschmar HA. Alpha-synuclein accumulation in a case of neurodegeneration with brain iron accumulation type 1 (NBIA-1, formerly Hallervorden-Spatz syndrome) with widespread cortical and brainstem-type Lewy bodies. Acta Neuropathol (Berl) 2000; 100: 568-574.
38. Newell FW, Johnson RO, Huttenlocher PR. Pigmentary degeneration of the retina in the Hallervorden-Spatz syndrome. Am J Ophthalmol 1979; 88: 467-471.
39. Odawara T, Iseki E, Yagishita S, Amano N, Kosaka K, Hasegawa K, Matsuda Y, Kowa H. An autopsied case of juvenile parkinsonism and dementia, with a widespread occurrence of Lewy bodies and spheroids. Clinical Neuropathology 1992; 11: 131-134.
40. Orrell RW, Amrolia PJ, Heald A, Cleland PG, Owen JS, Morgan-Hughes JA, Harding AE, Marsden CD. Acanthocytosis, retinitis pigmentosa, and pallidal degeneration: a report of three patients, including the second reported case with hypoprebetalipoproteinemia (HARP syndrome). Neurology 1995; 45: 487-492.
41. Park BE, Netsky MG, Betsill WL Jr. Pathogenesis of pigment and spheroid formation in Hallervorden-Spatz syndrome and related disorders. Neurology 1975; 25: 1172-1178.
42. Perry TL, Norman MG, Yong VW, Whiting S, Crichton JU, Hansen S, Kish SJ. Hallervorden-Spatz disease: cysteine accumulation and cysteine dioxygenase deficiency in the globus pallidus. Ann Neurol 1985; 18: 482-489.
43. Roid G, Miller L. Leiter International Performance Scale - Revised. Psychological Assessment Resources, Lutz, 1997.
44. Roth AM, Hepler RS, Mukoyama M, Cancilla PA, Foos RY. Pigmentary retinal dystrophy in Hallervorden-Spatz disease: clinicopathological report of a case. Surv Ophthalmol 1971; 16: 24-35.
45. Saito Y, Kawai M, Inoue K, Sasaki R, Arai H, Nanba E, Kuzuhara S, Ihara Y, Kanazawa I, Murayama S. Widespread expression of alpha-synuclein and tau immunoreactivity in Hallervorden-Spatz syndrome with protracted clinical course. J Neurol Sci 2000; 177: 48-59.
46. Searle AJ, Willson RL. Stimulation of microsomal lipid peroxidation by iron and cysteine. Characterization and the role of free radicals. Biochem J 1983; 212: 549-554.
47. Sener RN. Pantothenate kinase-associated neurodegeneration: MR imaging, proton MR spectroscopy, and diffusion MR imaging findings. AJNR Am J Neuroradiol 2003; 24: 1690-1693.
48. Sethi KD, Adams RJ, Loring DW, el Gammal T. Hallervorden-Spatz syndrome: clinical and magnetic resonance imaging correlations. Ann Neurol 1988; 24: 692-694.
49. Shevell M. Racial hygiene, active euthanasia, and Julius Hallervorden [see comments]. Neurology 1992; 42: 2214-2219.
50. Spatz H. Uber des Eisenmachweiss im Gehirn besonders in Zentren des extra-pyramidalmotorischen Systems. Z Gesamte Neurol Psychiatr 1922; 77: 261.
51. Sugiyama H, Hainfellner JA, Schmid-Siegel B, Budka H. Neuroaxonal dystrophy combined with diffuse Lewy body disease in a young adult. Clin Neuropathol 1993; 12: 147-152.
52. Swaiman KF, Smith SA, Trock GL, Siddiiqui AR. Sea-blue histiocytes, lymphocytic cytosomes, movement disorder and 59Fe-uptake in basal ganglia: Hallervorden-Spatz disease or ceroid storage disease with abnormal isotope scan? Neurology 1983; 33: 301-305.
53. Swaiman KF. Hallervorden-Spatz syndrome and brain iron metabolism. Archives of Neurology 1991; 48: 1285-1293.
54. Swisher CN, Menkes JH, Cancilla PA, Dodge PR. Coexistence of Hallervorden-Spatz disease with acanthocytosis. Trans Am Neurol Assoc 1972; 97: 212.
55. Szanto J, Gallyas F. A study of iron metabolism in neuropsychiatric patients. Hallervorden-Spatz disease. Arch Neurol 1966; 14: 438-442.
56. Tanfani G, Mascalchi M, Dal Pozzo GC, Taverni N, Saia A, Trevisan C. MR imaging in a case of Hallervorden-Spatz disease. J Comput Assist Tomogr 1987; 11: 1057-1058.
57. Taylor TD, Litt M, Kramer P, Pandolfo M, Angelini L, Nardocci N, Davis S, Pineda M, Hattori H, Flett PJ, Cilio MR, Bertini E, Hayflick SJ. Homozygosity mapping of Hallervorden-Spatz syndrome to chromosome 20p12.3-P13. Nature Genetics 1996; 14: 479-481.
58. The Psychological Corporation. Wechsler Abbreviated Scale of Intelligence. In: Harcourt, San Antonio, 1999.
59. Tripathi RC, Tripathi BJ, Bauserman SC, Park JK. Clinicopathologic correlation and pathogenesis of ocular and central nervous system manifestations in Hallervorden-Spatz syndrome. Acta Neuropathologica 1992; 83: 113-119.
60. Tuite PJ, Provias JP, Lang AE. Atypical dopa responsive parkinsonism in a patient with megalencephaly, midbrain Lewy body disease, and some pathological features of Hallervorden-Spatz disease. J Neurol Neurosurg Psychiatry 1996; 61: 523-7.
61. Vakili S, Drew A, Von Schuching S, Becker D, Zeman W. Hallervorden-Spatz syndrome. Arch Neurol 1977; 34: 729-738.
62. Volkl A, Ule G. Trace elements in human brain: Iron concentrations of 13 brain areas as a function of age. Neurology 1972; 202: 449-454.
63. Wakabayashi K, Yoshimoto M, Fukushima T, Koide R, Horikawa Y, Morita T, Takahashi H. Widespread occurrence of alpha-synuclein/NACP-immunoreactive neuronal inclusions in juvenile and adult-onset Hallervorden-Spatz disease with Lewy bodies. Neuropathol Appl Neurobiol 1999; 25: 363-368.
64. Williamson K, Sima AAF, Curry B, Ludwin SK. Neuroaxonal dystrophy in young adults: a clinicopathological study of two unrelated cases. Ann Neurol 1982; 11: 335-343.
65. World Healh Organization. WHO Laboratory Manual for the Examination of Human Sperm and Sperm-Cervical Interaction. 4. Cambridge. 138, 1999.
66. Yang EY, Campbell A, Bondy SC. Configuration of thiols dictates their ability to promote iron-induced reactive oxygen species generation. Redox Rep 2000; 5: 371-375.
67. Yoon SJ, Koh YH, Floyd RA, Park JW. Copper, zinc superoxide dismutase enhances DNA damage and mutagenicity induced by cysteine/iron. Mutat Res 2000; 448: 97-104.
68. Zhou B, Westaway SK, Levinson B, Johnson MA, Gitschier J, Hayflick SJ. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet 2001; 28: 345-349.